Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought
Tóm tắt
Từ khóa
Tài liệu tham khảo
Battaglia, 2019, Novel insights into the management of oligometastatic prostate cancer: a comprehensive review, Eur Urol Oncol, 2, 174, 10.1016/j.euo.2018.09.005
De Visschere, 2019, A systematic review on the role of imaging in early recurrent prostate cancer, Eur Urol Oncol, 2, 47, 10.1016/j.euo.2018.09.010
Rauscher, 2018, Efficacy, predictive factors, and prediction nomograms for 68ga-labeled prostate-specific membrane antigen–ligand positron-emission tomography/computed tomography in early biochemical recurrent prostate cancer after radical prostatectomy, Eur Urol, 73, 656, 10.1016/j.eururo.2018.01.006
Han, 2018, Impact of 68Ga-PSMA PET on the Management of patients with prostate cancer: a systematic review and meta-analysis, Eur Urol, 74, 179, 10.1016/j.eururo.2018.03.030
Gandaglia, 2015, Impact of the site of metastases on survival in patients with metastatic prostate cancer, Eur Urol, 68, 325, 10.1016/j.eururo.2014.07.020
Steuber, 2019, Standard of care versus metastases-directed therapy for PET-detected nodal oligorecurrent prostate cancer following multimodality treatment: a multi-institutional case-control study, Eur Urol Focus, 5, 1007, 10.1016/j.euf.2018.02.015
Kneebone, 2018, Stereotactic body radiotherapy for oligometastatic prostate cancer detected via prostate-specific membrane antigen positron emission tomography, Eur Urol Oncol, 1, 531, 10.1016/j.euo.2018.04.017
Aluwini, 2020, Oligometastatic prostate cancer: results of a Dutch multidisciplinary consensus meeting, Eur Urol Oncol, 3, 231, 10.1016/j.euo.2019.07.010
Montorsi, 2017, Robot-assisted salvage lymph node dissection for clinically recurrent prostate cancer, Eur Urol, 72, 432, 10.1016/j.eururo.2016.08.051
De Bleser, 2019, Metastasis-directed therapy in treating nodal oligorecurrent prostate cancer: a multi-institutional analysis comparing the outcome and toxicity of stereotactic body radiotherapy and elective nodal radiotherapy, Eur Urol, 76, 732, 10.1016/j.eururo.2019.07.009
Ost, 2015, Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature, Eur Urol, 67, 852, 10.1016/j.eururo.2014.09.004
Ost, 2018, Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial, J Clin Oncol, 36, 446, 10.1200/JCO.2017.75.4853
Siva, 2018, Stereotactic ablative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial, Eur Urol, 74, 455, 10.1016/j.eururo.2018.06.004
Phillips, 2019, Primary outcomes of a phase II randomized trial of Observation Versus Stereotactic Ablative RadiatIon for OLigometastatic Prostate CancEr (ORIOLE), Radiat Oncol Biol, 105, 681, 10.1016/j.ijrobp.2019.08.031
Fossati, 2019, Identifying the optimal candidate for salvage lymph node dissection for nodal recurrence of prostate cancer: results from a large, multi-institutional analysis, Eur Urol, 75, 176, 10.1016/j.eururo.2018.09.009
Ploussard, 2019, Salvage lymph node dissection for nodal recurrent prostate cancer: a systematic review, Eur Urol, 76, 493, 10.1016/j.eururo.2018.10.041
Mottet N., Bellmunt J., Briers E., et al. EAU – ESTRO – ESUR – SIOG guidelines on prostate cancer. https://Uroweb.org/Guideline/Prostate-Cancer/.
Rigatti, 2011, Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography, Eur Urol, 60, 935, 10.1016/j.eururo.2011.07.060
Briganti, 2012, Lymphatic spread of nodal metastases in high-risk prostate cancer: the ascending pathway from the pelvis to the retroperitoneum, Prostate, 72, 186, 10.1002/pros.21420
Devos, 2019, Comparison of peri-operative and early oncological outcomes of robot-assisted vs. open salvage lymph node dissection in recurrent prostate cancer, Front Oncol, 9, 781, 10.3389/fonc.2019.00781
Clavien, 2009, The Clavien-Dindo classification of surgical complications, Ann Surg, 250, 187, 10.1097/SLA.0b013e3181b13ca2
Touijer, 2018, Survival outcomes of men with lymph node-positive prostate cancer after radical prostatectomy: a comparative analysis of different postoperative management strategies, Eur Urol, 73, 890, 10.1016/j.eururo.2017.09.027
Suardi, 2017, Salvage lymph node dissection for node-only recurrence of prostate cancer: ready for prime time?, Eur Urol, 71, 693, 10.1016/j.eururo.2016.12.001
Osmonov, 2016, Cancer-specific and overall survival in patients with recurrent prostate cancer who underwent salvage extended pelvic lymph node dissection, BMC Urol, 16, 56, 10.1186/s12894-016-0173-3
Porres, 2016, The role of salvage extended lymph node dissection in patients with rising PSA and PET/CT scan detected nodal recurrence of prostate cancer, Prostate Cancer Prostatic Dis, 20, 85, 10.1038/pcan.2016.54
Hiester, 2019, Oncological outcome of patients treated with spot-specific salvage lymph node dissection (sLND) for positron-emission tomography (PET)-positive prostate cancer (PCa) relapse, World J Urol, 37, 2081, 10.1007/s00345-019-02633-w
Abdollah, 2015, Contemporary role of salvage lymphadenectomy in patients with recurrence following radical prostatectomy, Eur Urol, 67, 839, 10.1016/j.eururo.2014.03.019
Suardi, 2015, Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years, Eur Urol, 67, 299, 10.1016/j.eururo.2014.02.011
Cucchiara, 2018, Genomic markers in prostate cancer decision making, Eur Urol, 73, 572, 10.1016/j.eururo.2017.10.036
Xu, 2019, Genomic risk predicts molecular imaging-detected metastatic nodal disease in prostate cancer, Eur Urol Oncol, 2, 685, 10.1016/j.euo.2018.11.002
Knipper, 2019, Metastases-yield and prostate-specific antigen kinetics following salvage lymph node dissection for prostate cancer: a comparison between conventional surgical approach and prostate-specific membrane antigen-radioguided surgery, Eur Urol Focus, 5, 50, 10.1016/j.euf.2018.09.014
European Organisation for Research and Treatment of Cancer Radiotherapy and Genito-Urinary Cancer Groups, 2006, Impact of pathology review of stage and margin status of radical prostatectomy specimens (EORTC trial 22911), Virchows Arch, 449, 428, 10.1007/s00428-006-0254-x
Bravi, 2019, The impact of experience on the risk of surgical margins and biochemical recurrence after robot-assisted radical prostatectomy: a learning curve study, J Urol, 202, 108, 10.1097/JU.0000000000000147
Bravi, 2018, Relative contribution of sampling and grading to the quality of prostate biopsy: results from a single high-volume institution, Eur Urol Oncol